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according to the tumor-node-metastasis (TMN) classification system published by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) in 2003 [24] (9 patients  were stage I, 14 were stage II, 28 were stage III, and 15 were stage IV; 10 were Tx-T1, 17 were T2, 24 were  T3, and 15 were T4; 8 were T0, 17 were N1, 12 were N2, and 29 were N3; 66 were M0). No patient showed distant metastasis, and the diagnosis of non-keratinizing squamous cell carcinoma was according to two well-experienced pathologists using complete pathological data. The exclusion criteria were as follows: NPC patients with other tumors and NPC patients with serious diseases affecting other organ systems, including cardiovascular and cerebrovascular diseases, diabetes, uremia, severe hepatic and renal dysfunction, myasthenia gravis and malnutrition. As controls, 17 biopsy specimens of nasopharyngeal mucosa were selected from the ear-nose-throat department.
Immunohistochemical staining
Immunohistochemical staining was performed using a commercial kit according to the manufacturer's instructions (Zymed Company). The paraffin sections were dewaxed with xylene, hydrated through an alcohol gradient and then immersed in 3% H 2 O 2 for 5 min to remove endogenous peroxidase, followed by high-temperature antigen retrieval in ethylene diamine tetraacetic acid (EDTA). After cooling, the sections were rinsed with phosphate-buffered saline (PBS, 5 min´ 3 times) and incubated in normal goat serum (room temperature, 30 min) to block non-specific antigens. Antibodies against TGFβRI (1:100; No. BA0294, BOSTER Biological Technology Co., Ltd., Wuhan, China), PDCD4 (1:50; No. 7975; MT-Biotechnology Co., Ltd., Shanghai, China) and c-Jun (1:50; No. A02038; BOSTER Biological Technology Co., Ltd., Wuhan, China) were diluted and incubated with the sections (first at 4°C overnight and then at room temperature for 30 min). Following three rinses with PBS, biotin-labeled secondary antibodies were added; the sections were then incubated at 37°C for 20 min, rinsed again three times with PBS, and stained with diaminobenzidine (DAB). The staining reaction was halted with tap water at the appearance of a clear positive result under the microscope. Subsequently, the sections were counterstained with hematoxylin and then washed with running water, followed by baking (60°C, 1 h) and blocking with resinene. A microscope was used for observation. Staining was performed using the method proposed by Masunaga et al [25] . Each section was observed in 5 randomly selected, high-power fields, and each field contained 100 cells. The sections were scored based on the proportion of positive cells as follows: < 5% positive cells, 0 points; 5 -25% positive cells, 1 point; 26 -50% positive cells, 2 points; > 50% positive cells, 3 points. The color intensity of the stained cells was also scored, as follows: colorless, 0 points; light yellow, 1 point; yellow or brownish yellow, 2 points; brown, 3 points. The final score for each section was calculated as the sum of the two scores. High expression (positive expression, +) referred to a sum 3 points, whereas low expression (negative expression, -) referred to a sum < 3 points.
Follow-up
After the end of treatment, 66 patients were randomly followed up through outpatient services, hospitalization and phone contacts, with a duration varying from 6 to 60 months (median, 42 months). During the follow-up period, 20 patients experienced local recurrence, and 23 experienced distant metastasis. Prognosis was evaluated according to OS and progression-free-survival (PFS). PFS was defined as the duration from the day treatment ended to the day tumor progression or death occurred. OS referred to the period from the day treatment ended to the day death occurred.
Cell culture
The human NPC cell line CNE2 (No. ZY-H362, Shanghai Ze Ye Biological Technology Co., Ltd, Shanghai, China) was routinely cultured in 6-well plates in a 95% air/5% CO 2 incubator at 37°C using Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). When the cells reached the logarithmic growth phase, the medium was replaced with serum-free DMEM. The cells were then assigned to either a control group (no treatment) or an inhibitor group (treated with 50 nM SB431542, a TGFβRI inhibitor; No. HPBIO181007, Hepeng Biological Technology Co., Ltd, Shanghai, China). After 24 hours, the cells were collected at 4°C, and total protein was extracted.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry (PMSF). The cells were homogenized at 3000 r/min until sufficiently lysed and placed on ice for 30 min, after which they were centrifuged at 12, 000 × g for 4 min. The supernatant was collected and stored at -80°C. The protein concentration was assessed using a commercial bicinchoninic acid (BCA) kit according to the manufacturer's instructions (BOSTER Biological Technology Co., Ltd., Wuhan, China), and the concentration of each sample was adjusted to 3 μg/μl. The extracted protein was mixed with sample buffer and boiled at 100°C for 10 min, and 30 μg was separated by 10% polyacrylamide gel electrophoresis (PAGE). The proteins were then transferred onto polyvinylidene fluoride (PVDF) membranes (No. P2438, SigmaAldrich, St. Louis, MO, USA) using a semi-dry electroblotting technique, and the membranes were incubated with 5% bovine serum albumin (BSA) at room temperature for 1 h. Anti-rabbit primary antibodies against TGFβRI (1:5000; ab180619, Abcam, Inc., MA, USA), PDCD4 (1:2000, ab51495, Abcam, Inc., MA, USA) or c-Jun (1:1000; ab32137, Abcam, Inc., MA, USA) were added, and the membranes were incubated at 4°C overnight. The membranes were rinsed in Tris-buffered saline (TBS)/Tween-20 (TBST) 3 times for 5 min each. The corresponding goat anti-rabbit secondary antibody (ab150077, Abcam, Inc., MA, USA) was added and incubated for 1 h, after which the membranes were again washed 3 times for 5 min each. Chemiluminescent reagent (No. NCI 5080, Yanhui Biology Ltd., Shanghai, China) was applied to develop the protein bands. Glyceraldehyde-phosphate dehydrogenase (GADPH) was used as an internal reference. A Bio-Rad Gel Doc EZ imager (Bio-Rad, Richmond, California, USA) was used for visualization, and gray-value analysis was performed using Image J software (National Institutes of Health).
Statistical analysis
Data analysis was performed using SPSS 21.0 (SPSS Inc., Chicago, IL, USA). Categorical data are expressed as frequencies or percentages, and comparisons among multiple groups were carried out using the chi-square test. Correlations were analyzed using Spearman rank correlation analysis. Survival rates were calculated using the Kaplan-Meier method. Comparisons between two groups were achieved using the log-rank test, and prognostic factors were screened using a Cox regression model. P < 0.05 indicated statistical significance.
Results

Localization of TGFβRI, PDCD4, and AP-1 (c-Jun) determined by immunohistochemical staining in NPC and normal tissues
Immunohistochemical staining (Fig. 1 ) revealed positive TGFβRI expression in plasma membranes and cytoplasm. Positive PDCD4 and AP-1 (c-Jun) expression was found in the nucleus and partially in the cytoplasm, appearing as brownish yellow granules.
NPC tissues showed increased expression of TGFβRI and AP-1 and decreased expression of PDCD4 compared with normal tissues
In comparison with normal tissues, NPC tissues showed increased expression of TGFβRI (72.73% vs. 23.53%, P < 0.01) and AP-1 (77.27% vs. 11.76%, P < 0.05) and reduced expression of PDCD4 (39.40% vs. 76.47%, P < 0.05) ( Table 1 ). 
Association between TGFβRI, PDCD4, and AP-1 expression levels and clinicopathological features of NPC As shown in Table 2 , the expression levels of TGFβRI, AP-1 and PDCD4 varied in patients with different tumor and node stages. Compared with those who were T3-T4 and N1-N3, significantly reduced expression of TGFβRI and AP-1 and significantly higher expression of PDCD4 was observed in patients at Tx-T2 and N0 (all P < 0.05). In addition, PDCD4 expression was significantly decreased and TGFβRI and c-Jun expression significantly increased in patients with < 5 years survival than those with > 5 years survival (all P < 0.05). However, no significant differences in TGFβRI, AP-1 or PDCD4 expression was found when comparing patients based on gender or age (all P > 0.05).
Correlations among expression levels of TGFβRI, AP-1 and PDCD4 in NPC Spearman analysis revealed (Table 3) that TGFβRI expression positively correlated with AP-1 expression (r > 0, P < 0.05) and that both TGFβRI and AP-1 expression negatively correlated with PDCD4 expression (r < 0, r < 0, both P < 0.05).
Association between TGFβRI, PDCD4, and AP-1 expression and NPC patient survival
The 5-year OS and 5-year PFS were calculated using the Kaplan-Meier method ( Table 2 . Associations between TGFβRI, PDCD4, and AP-1 and clinicopathological features of NPC. Note: AP-1, activator protein-1; PDCD4, programmed cell. Note: AP-1, activator protein-1; PDCD4, programmed cell death 4; TGFβRI, transforming growth factor-β receptor I; OS, overall survival; NPC, nasopharyngeal carcinoma 
High expression of TGFβRI and AP-1 and low expression of PDCD4 were risk factors for OS and PFS
Cox regression analysis demonstrated ( Table 4 ) that advanced tumor and node stage, TGFβRI over-expression (OS: relative risk = 1.255, P < 0.05; PFS: relative risk = 1.870, P < 0.05), AP-1 over-expression (OS: relative risk = 1.251, P < 0.05; PFS: relative risk = 1.223, P < 0.05) and PDCD4 under-expression (OS: relative risk = 1.162, P < 0.05; PFS: relative risk = 1.160, P < 0.05) were unfavorable risk factors for OS and PFS. 
Decreased TGFβRI expression up-regulated PDCD4 expression, as shown by western blotting Western blotting (Fig. 3) revealed that TGFβRI and AP-1 (c-Jun) expression decreased and PDCD4 expression increased in the CNE2 cells treated with inhibitor compared with the control group, and these changes were significant (all P < 0.05). These results indicate that down-regulation of TGFβRI expression increases PDCD4 expression, thus reducing AP-1 (c-Jun) expression.
Discussion
NPC is an Epstein Barr virus (EBV)-associated malignancy with higher metastatic potency than other head and neck cancers due to persistent EBV infection and the presence of immune cell infiltration around tumor lesions [26] . NPC is poorly differentiated and characterized by invasive growth into surrounding tissues and frequent metastasis [27] . Recent reports of the causes of NPC are helping to improve the cure rate.
In the present study, we found that NPC tissues show higher expression of TGFβRI and AP-1 and lower expression of PDCD4 compared with normal tissues. A previous study demonstrated that TGFβ expression in tumor cells is promoted by surrounding cells in the tumor microenvironment [28] . It has been reported that TGF-β1 was overexpressed in several cancers such as hepatocellular carcinoma and it was related to the progression of tumor cells [29, 30] . AP-1 helps to regulate host immune responses and is up-regulated in many types of cancer, including breast cancer and pancreatic cancer [31] [32] [33] . AP-1 activation in patients with NPC is mediated by latent membrane protein 1 (LMP-1), which is encoded by EBV. LMP-1 induces transcription of P53 by regulating AP-1 protein expression, and increased P53 may in turn lead to activation and increased expression of AP-1 [34] . A study conducted by Gao et al. showed that loss of PDCD4 expression is common in human glioma and may partially contribute to tumor development [35] . Another previous study suggested that TGFβ1 activity may be activated by AP-1 and that TGFβ, the receptor of which is TGFβRI, plays an important role in the progression of chronic renal disease [36] . Over-expression of PDCD4 in RT101 cells has been reported to inhibit AP-1 transactivation, possibly resulting from inhibition of Jun or Fos protein synthesis, sequestration of Jun or Fos proteins, or suppression of Jun or Fos protein activation [37] . Furthermore, PDCD4 has been shown to impede tumor progression in human colon carcinoma cells by down-regulating mitogenactivated protein kinase 1 (MAP4K1) transcription, with consequent inhibition of AP-1-dependent transcription and c-Jun activation [38] . Our study also revealed that TGFβRI-positive patients and AP-1-positive patients have significantly reduced 5-year OS and 5-year PFS and that over-expression of TGFβRI and AP-1 and decreased PDCD4 expression are unfavorable risk factors for NPC. A prior study reported that advanced NPC is often associated with high expression of TGFβ1, which regulates tumor proliferation. Additionally, over-expression of TGFβ1 may overcome factors affecting the negative regulation of TGFβ1 and thereby further accelerate disease progression, leading to a poor prognosis in patients with advanced NPC [16] . Moreover, the transcription factor activity of AP-1 might play an essential role in mediating NPC metastasis, and AP-1 is a novel and effective target for the treatment or prevention of LMP1-positive NPC [39] . Chen et al. proposed that a lack of PDCD4 protein expression is associated with an adverse prognosis in patients with lung cancer, with a mean survival time of 47 months for patients with PDCD4-positive tumors compared to only 22 months for those with PDCD4-negative tumors [40] . Additional research showed that one possible mechanism by which PDCD4-positive expression improves patient prognosis occurs through PDCD4's activity as a suppressor of tumorigenesis, transformation and invasion. PDCD4 also plays a role in suppressing tumor intravasation, and inhibition of PDCD4 can be achieved by regulating u-PAR gene expression [41] .
In conclusion, our study provides evidence that TGFβRI and AP-1 expression levels are elevated in NPC, whereas PDCD4 expression is decreased. These results suggest that the TGFβ/PDCD4/AP-1 pathway is associated with NPC development and progression. Furthermore, high expression of TGFβRI and AP-1 and low expression of PDCD4 may be unfavorable prognostic factors for patients with NPC. Spearman rank correlation analysis showed TGFβRI expression to be positively correlated with AP-1 expression and TGFβRI and AP-1 expression to be negatively correlated with PDCD4 expression. However, resource limitations prevented us from further exploring the mechanism underlying how TGFβRI targets PDCD4. Future studies investigating this mechanism and aimed at identifying intermediate targets responsible for TGFβRI-mediated regulation of PDCD4 should prove worthwhile.
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